Fate Therapeutics Q1 cash $641.7M, rev $18.4M; FT596+R-CHOP IND, FT536 solid tumor on track

FATE THERAPEUTICS INC

2023-Q1 EPS reported -$0.68 revenue$18,414,000

Q1 2022 revenue of $18.4M from Janssen/Ono collaborations; R&D expense $72.1M, G&A $20.7M.
Cash, equivalents and investments $641.7M as of March 31, 2022.
FT596+R-CHOP clinical protocol for first-line aggressive lymphoma to be submitted to FDA in 2Q22.
FT536 CAR MICA/B NK cell product candidate on track for first patient treatment in 2Q22.
Third IND candidate nominated under Janssen collaboration triggering preclinical milestone payment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.